TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30153382
Drug: Levothyroxine sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Levothyroxine sodium soft capsule (4 × 150-μg capsules) with water
Study: 25265768
Drug: Neostigmine 2.5
Normalized name: neostigmine 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neostigmine 2.5 mg, glycopyrrolate 0.2 mg and atropine 0.6 mg
Study: 22459700
Drug: Active radiation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active radiation treatment (890-nm wavelength, 6 sessions of 40 minutes each)
Study: 22459700
Drug: Placebo radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo radiation treatment
Study: 22459700
Drug: Active radiation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active radiation treatment (890-nm wavelength)
Study: 20064223
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) implemented in 11 health sub-districts.
Study: 9118819
Drug: Dexfenfluramine 15mg
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 15mg twice daily with dietary support
Study: 1396480
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran concentrate (11.2 g of beta-glucan daily)
Study: 21248153
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug users (IDUs)
Study: 18314197
Drug: Injection drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection drug users (IDUs) without endocarditis
Study: 12633131
Drug: Selegiline transdermal
Normalized name: Selegiline Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline transdermal system (STS), 20 mg/20 cm², daily for up to 8 weeks
Study: 11862376
Drug: Cortisol (hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (hydrocortisone 20 mg)
Study: 10207191
Drug: Carisolv method
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carisolv method (gel treatment)
Study: 2189417
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of ciamexon
Study: 2189417
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day of ciamexon
Study: 219802
Drug: Estrogen therapy
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen therapy (large doses of oral conjugated estrogen for three months)
Study: 219802
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered for a comparable period)
Study: 6341417
Drug: Timolol-Hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol-Hydrochlorothiazide combination
Study: 22723573
Drug: Teriflunomide 7
Normalized name: teriflunomide 7 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriflunomide 7 mg once daily
Study: 10918432
Drug: Oral granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral granisetron
Study: 8849763
Drug: One enema,
Approvals — FDA: no, EMA: no, PMDA: no
Description: One enema, self administered at home two hours before the test
Study: 8849763
Drug: Two enemas,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two enemas, administered the night before and two hours before the test
Study: 1378141
Drug: Nifedipine sustained-release
Normalized name: nifedipine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine sustained-release 20 mg twice daily
Study: 1378141
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of carvedilol and nifedipine SR
Study: 1378141
Drug: Monotherapy (either
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (either carvedilol or nifedipine SR)
Study: 30030308
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no pharmacist-led medication review)
Study: 26838248
Drug: Mouth-rinse with
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth-rinse with G-CSF (150-300ug plus 100ml-500ml normal saline) for at least 7 days
Study: 26838248
Drug: Mouth-rinse with
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mouth-rinse with G-CSF
Study: 22532515
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg intravenous once yearly
Study: 9893190
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol dry powder 1600 microg
Study: 9893190
Drug: Inhaled albuterol
Normalized name: albuterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled albuterol dry powder after placebo pretreatment
Study: 1675877
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (n = 9)
Study: 27130812
Drug: Caregivers who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caregivers who perceived it easy to remember medication names
Study: 27130812
Drug: Caregivers who
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caregivers who did not easily remember medication names
Study: 20562295
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM L-NAME
Study: 20562295
Drug: Combined 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined 4 mM theophylline + 10 mM L-NAME
Study: 20562295
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (control)
Study: 18589032
Drug: Higher dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher dietary protein intake (0.62 g/kg body weight/day)
Study: 16025960
Drug: Drug-therapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-therapy plus acupuncture (Group B)
Study: 16025960
Drug: Drug-therapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-therapy plus ETSM and acupuncture (Group C)
Study: 16025960
Drug: Drug-therapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-therapy only (Group A)
Study: 10099859
Drug: Ambulatory withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory withdrawal therapy
Study: 10099859
Drug: Stationary withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stationary withdrawal therapy
Study: 8911442
Drug: 4 annual
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 annual doses of ivermectin
Study: 8911442
Drug: 10 6‐monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 6‐monthly doses of ivermectin
Study: 6137895
Drug: Opiate analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opiate analgesics (omnopon, pethidine, pentazocine)
Study: 6312664
Drug: Naloxone (opiate/opioid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (opiate/opioid antagonist)
Study: 20740477
Drug: HandTutor™ combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: HandTutor™ combined with traditional therapy
Study: 15136304
Drug: Enoxaparin sodium
Normalized name: Enoxaparin Sodium
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enoxaparin sodium (low-molecular-weight heparin)
Study: 11517856
Drug: Cetirizine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (10 mg/three times a day for 15 days)
Study: 7560252
Drug: Iloperidone 3
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 3 mg
Study: 7560252
Drug: Iloperidone 5
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone 5 mg
Study: 837172
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g or 200 g of liquorice daily for one to four weeks
Study: 30777001
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg modafinil taken daily for 6 weeks
Study: 23444345
Drug: Craniospinal radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Craniospinal radiotherapy (23.4 Gy) plus adjuvant chemotherapy
Study: 22064991
Drug: Nicotine 2
Normalized name: nicotine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 2 mg
Study: 22064991
Drug: Nicotine 4
Normalized name: nicotine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 4 mg
Study: 22064991
Drug: Nicotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2 mg and 4 mg)
Study: 10668837
Drug: Nonusers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers of antihypertensive drugs
Study: 7490809
Drug: Anticholinergic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic therapy for detrusor instability
Study: 1593852
Drug: Triple treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple treatment (low-dose cyclosporine, azathioprine, methylprednisolone)
Study: 1593852
Drug: Combinations of
Normalized name: Combinations of vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations of two immunosuppressive drugs
Study: 30795785
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day crocin (2 plus crocin tablet, 15 mg BID)
Study: 30795785
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 tablets per day, 15 mg BID)
Study: 19856040
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg isobaric mepivacaine 1.5% plus 10 microg fentanyl (M + F group)
Study: 19856040
Drug: 45 mg
Normalized name: lutein 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 mg isobaric mepivacaine 1.5% (M group)
Study: 17643363
Drug: Low dialysate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dialysate calcium (LCD) 1.25 mmol/l
Study: 17643363
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium dialysate (HCD) 1.75 mmol/l
Study: 16008972
Drug: BiPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BiPAP therapy
Study: 12221159
Drug: Amantadine (usually
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amantadine (usually 400 mg/d)
Study: 8554732
Drug: Acute losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute losartan therapy (50 mg single dose)
Study: 8554732
Drug: Chronic losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic losartan therapy (42 days)
Study: 122333
Drug: Cimetidine 1g
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine 1g daily for 4 weeks
Study: 122333
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets of identical appearance for 4 weeks
Study: 31127837
Drug: Group acupuncture
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acupuncture (once weekly for 12 weeks)
Study: 31127837
Drug: Group acupuncture
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acupuncture (twice weekly for 12 weeks)
Study: 31127837
Drug: Group acupuncture
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acupuncture (once or twice weekly for 12 weeks)
Study: 28103704
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation counseling and nicotine patches
Study: 25482435
Drug: Home administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home administration of 200mg mifepristone
Study: 25482435
Drug: Clinic administration
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic administration of 200mg mifepristone
Study: 8203982
Drug: Low-dose GH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose GH (0.1 mg/kg)
Study: 8203982
Drug: High-dose GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose GH (0.2 mg/kg)
Study: 3316514
Drug: Cyclophosphamide monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide monotherapy
Study: 12612277
Drug: Aqueous nasal
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous nasal beclomethasone (400 micro g/d for 4 weeks, then 200 micro g/d for 24 weeks)
Study: 12612277
Drug: Aqueous nasal
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous nasal beclomethasone (200 micro g/d for 24 weeks)
Study: 8627081
Drug: Antibody levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody levels to pertussis toxin (PT) measured by ELISA
Study: 8627081
Drug: Antibody levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody levels to filamentous hemagglutinin (FHA) measured by ELISA
Study: 8627081
Drug: Antibody levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody levels to PT and FHA
Study: 1750720
Drug: Uniphyl tablets
Normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniphyl tablets taken with food
Study: 1750720
Drug: Uniphyl tablets
Normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uniphyl tablets taken under fasting conditions
Study: 7149102
Drug: Oxamniquine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (20 mg/kg a day for 3 days)
Study: 7149102
Drug: Niridazole (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niridazole (15 mg/kg a day for 8 days)
Study: 26012289
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (parents record daily symptom scores and receive short messages from doctors)
Study: 26012289
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (parents do not record daily symptom scores and do not receive short messages)
Study: 17418836
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of acarbose
Study: 15119636
Drug: Dialysate volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate volume of 2.0 L
Study: 15119636
Drug: Dialysate volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate volume of 2.5 L
Study: 15119636
Drug: Dialysate volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate volume of 3.0 L
Study: 11515707
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg daily (increased to 10 mg if BP > 140/90 mmHg)
Study: 11515707
Drug: Nifedipine retard
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine retard 20 mg twice daily (increased to 40 mg if BP > 140/90 mmHg)
Study: 8632551
Drug: Vacuum therapy
Normalized name: Rapport Vacuum Therapy Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum therapy
Study: 2842677
Drug: Monovalent Japanese
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent Japanese encephalitis vaccine (n = 21,628)
Study: 2842677
Drug: Bivalent Japanese
Normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent Japanese encephalitis vaccine (n = 22,080)
Study: 2842677
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine groups combined
Study: 18817474
Drug: LLLT (655
Approvals — FDA: no, EMA: no, PMDA: no
Description: LLLT (655 nm) of 5 J at an energy density of 500 J/cm2 administered at four points along the biceps muscle belly
Study: 18817474
Drug: Placebo LLLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo LLLT administered in the same manner
Study: 16580286
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) followed by oral nifidepine tocolysis (n = 24)
Study: 10808210
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B colloidal dispersion (ABCD) 2 mg/kg/day intravenously
Study: 10808210
Drug: Fluconazole 200
Normalized name: fluconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 200 mg/day orally
Study: 8827784
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) therapy for 1 week
Study: 8827784
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) therapy for 1 week (after discontinuation)
Study: 1306636
Drug: Beclomethasone Dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate per nasal spray (400 mcg a day)
Study: 1306636
Drug: Antihistaminical drugs
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistaminical drugs or ketotifen per os and Disodium chromoglycate per nasal spray
Study: 12351279
Drug: Oral desipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desipramine
Study: 28341415
Drug: Diuretic strategy
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic strategy based on CA125: high dose if CA125 > 35 U/mL, low doses otherwise
Study: 28341415
Drug: Standard diuretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diuretic strategy: titration based on conventional clinical and biochemical evaluation
Study: 28341415
Drug: Diuretic strategy
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic strategy based on CA125
Study: 25981372
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 4 kcal/min (ID4)
Study: 25981372
Drug: Intraduodenal glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraduodenal glucose infusion at 2 kcal/min (ID2)
Study: 23063790
Drug: Phonophoresis of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis of piroxicam (PhP) with 4 grams of 0.5% piroxicam gel, 20mg of piroxicam drug, ultrasound program, continuous mode, 1.0W/cm(2), 10 minutes per session, 5 times per week for 2 weeks.
Study: 23063790
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (UT) using nondrug coupling gel, ultrasound program, continuous mode, 1.0W/cm(2), 10 minutes per session, 5 times per week for 2 weeks.
Study: 21750201
Drug: Cixutumumab (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cixutumumab (6 mg/kg IV) and Temsirolimus (25 mg IV)
Study: 14708410
Drug: H2RA-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin, 0.4 g metronidazole) for 1 week
Study: 14708410
Drug: H2RA-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin, 0.4 g metronidazole) for 2 weeks
Study: 14708410
Drug: PPI-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin, 0.4 g metronidazole) for 1 week
Study: 14708410
Drug: PPI-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin, 0.4 g metronidazole) for 2 weeks
Study: 10829335
Drug: 12-Step, Minnesota
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-Step, Minnesota Model treatment (completed treatment)
Study: 10829335
Drug: 12-Step, Minnesota
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-Step, Minnesota Model treatment (incomplete treatment)
Study: 9305460
Drug: lorazepam 2
Normalized name: lorazepam 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lorazepam 2 mg
Study: 8321672
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of essential oils of lavender species 1
Study: 8321672
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of essential oils of lavender species 2
Study: 2425156
Drug: Pindolol (0.02
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (0.02 mg/kg i.v.)
Study: 2425156
Drug: Propranolol and
Normalized name: propranolol and thiazides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol and Pindolol (both drugs during exercise)
Study: 29996883
Drug: Repeated non-surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated non-surgical periodontal therapy
Study: 29996883
Drug: Standard-of-care and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care and Repeated non-surgical periodontal therapy
Study: 10485385
Drug: Sublingual-swallow immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets)
Study: 2201256
Drug: 1-hour infusion
Normalized name: coagulation factor IX recombinant immunoglobulin G1 fusion protein 1 UNT [Alprolix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour infusion of amphotericin B (group A)